Real-World use of clotting factor in iraqi haemophilia patients examined

NCT ID NCT06574984

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-world treatment patterns, not to change how patients were treated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: turoctocog alfa (a clotting factor VIII replacement therapy)
What this could lead to: If successful, this study could help doctors understand how turoctocog alfa is used in real-world settings and guide better management of haemophilia A.
What could go wrong: This is an observational study that only looks back at existing records, so it cannot prove cause and effect. Results may not apply to other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL BLEEDING DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL BLEEDING DISORDER HAEMOPHILIA A

Contacts and locations

Locations

Basrah Haemoplhilia centre

Basra, 61001, Iraq
Hilla Haemophilia centre

Hillah, 51001, Iraq
Karbala Haemophilia centre

Karbala, 56001, Iraq
Kirkuk Centre for Cancer and Blood Disorders

Kirkuk, 36001, Iraq
Najaf Haemophilia Centre

Najaf, 54001, Iraq
National centre for Hamophilia

Baghdad, 10001, Iraq
Novo Nordisk Investigational Site

Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.